Cellular Therapies in Critical Illness: Current Evidence and Future Directions

Dr Neeraj Manikath , claude.ai

Abstract

Background: Cellular therapies, particularly mesenchymal stem cells (MSCs), have emerged as promising therapeutic modalities for critical illness syndromes including acute respiratory distress syndrome (ARDS) and septic shock. Despite extensive preclinical evidence demonstrating immunomodulatory and regenerative properties, clinical translation has faced significant challenges.

Objective: To provide a comprehensive review of current evidence for cellular therapies in critical care, focusing on MSC applications in ARDS and septic shock, and evaluate recent clinical trial developments through 2025.

Methods: We conducted a systematic review of published literature, ongoing clinical trials, and regulatory developments in cellular therapy for critical illness through September 2025.

Results: While preclinical studies consistently demonstrate MSC efficacy in reducing inflammation and promoting tissue repair, clinical trials have shown mixed results. Recent phase II/III trials have refined patient selection criteria, dosing strategies, and timing of administration. Novel cell products including MSC-derived exosomes and genetically modified cells show promise in early-phase studies.

Conclusions: Cellular therapies remain investigational in critical care settings. Success in future trials will likely depend on precision medicine approaches, standardized manufacturing protocols, and biomarker-guided patient selection.

Keywords: Mesenchymal stem cells, ARDS, septic shock, cellular therapy, critical care, immunomodulation

Introduction

Critical illness syndromes such as acute respiratory distress syndrome (ARDS) and septic shock represent major causes of morbidity and mortality in intensive care units worldwide. Despite advances in supportive care, mortality rates remain substantial, with ARDS mortality ranging from 30-45% and septic shock approaching 40-50%¹,². The pathophysiology of these conditions involves complex inflammatory cascades, endothelial dysfunction, and tissue injury that often prove refractory to conventional therapeutic approaches.

Cellular therapies, particularly mesenchymal stem cells (MSCs), have garnered significant attention as potential therapeutic interventions for critical illness. MSCs possess unique properties including immunomodulation, anti-inflammatory effects, antimicrobial activity, and tissue repair capabilities³. These characteristics make them theoretically attractive for conditions characterized by dysregulated inflammation and tissue injury.

This review synthesizes current evidence for cellular therapies in critical care, with emphasis on MSC applications in ARDS and septic shock, while highlighting recent clinical trial developments and future directions in this rapidly evolving field.

Mesenchymal Stem Cells: Biological Rationale

Cellular Characteristics and Mechanisms of Action

MSCs are multipotent stromal cells that can be isolated from various tissues including bone marrow, adipose tissue, umbilical cord, and placenta⁴. The International Society for Cellular and Gene Therapies (ISCT) has established minimal criteria for MSC identification: plastic adherence, specific surface antigen expression (CD105+, CD73+, CD90+, CD45-, CD34-, CD14-), and tri-lineage differentiation potential⁵.

Pearl: The therapeutic effects of MSCs are primarily mediated through paracrine mechanisms rather than direct cellular engraftment and differentiation. This paradigm shift has important implications for dosing and delivery strategies.

The proposed mechanisms of MSC action in critical illness include:

Immunomodulation: MSCs secrete anti-inflammatory cytokines (IL-10, TGF-β) while suppressing pro-inflammatory mediators (TNF-α, IL-1β, IL-6)⁶
Antimicrobial effects: Production of antimicrobial peptides including LL-37, β-defensin-2, and indoleamine 2,3-dioxygenase⁷
Endothelial protection: Secretion of angiogenic factors (VEGF, angiopoietin-1) and barrier-protective mediators⁸
Tissue repair: Release of growth factors promoting epithelial and endothelial repair⁹

MSC Sources and Considerations

Different MSC sources exhibit varying characteristics relevant to critical care applications:

Bone marrow-derived MSCs (BM-MSCs): Most extensively studied, gold standard for comparison
Adipose-derived MSCs (AD-MSCs): More abundant, potentially superior anti-inflammatory properties¹⁰
Umbilical cord MSCs (UC-MSCs): Younger cells with potentially enhanced regenerative capacity, no ethical concerns¹¹
Placental MSCs: High proliferative capacity, strong immunosuppressive properties¹²

Hack: Allogeneic MSCs may be preferable to autologous cells in critically ill patients due to the immunocompromised state and cellular dysfunction associated with critical illness, which may impair autologous MSC function.

MSCs in Acute Respiratory Distress Syndrome

Pathophysiology and Therapeutic Targets

ARDS is characterized by acute onset of bilateral pulmonary infiltrates, impaired oxygenation, and increased alveolar-capillary permeability not fully explained by cardiac failure¹³. The pathophysiology involves:

Inflammatory phase: Neutrophil infiltration, pro-inflammatory cytokine release
Proliferative phase: Type II pneumocyte proliferation, fibroblast activation
Fibrotic phase: Collagen deposition, architectural distortion

MSCs theoretically address multiple pathophysiological targets in ARDS through their anti-inflammatory, antimicrobial, and tissue repair properties.

Preclinical Evidence

Extensive preclinical studies have demonstrated MSC efficacy in animal models of ARDS. Key findings include:

Reduced pulmonary inflammation and neutrophil infiltration¹⁴
Improved alveolar-capillary barrier function¹⁵
Enhanced bacterial clearance in pneumonia models¹⁶
Reduced pulmonary fibrosis in later-phase injury¹⁷

Oyster: Despite consistent preclinical efficacy, the translation to human clinical trials has been challenging, highlighting the limitations of animal models in recapitulating human ARDS complexity.

Clinical Trial Evidence

Early Phase Studies

STAIR (START Trial - Phase I): Wilson et al. conducted the first-in-human safety study of bone marrow-derived MSCs in ARDS patients¹⁸. Nine patients received escalating doses (1, 5, and 10 million cells/kg) with no significant safety concerns identified.

STAIR Phase II: Subsequently, Matthay et al. published results from a randomized, double-blind, placebo-controlled phase II trial of 60 patients with moderate-to-severe ARDS¹⁹. Patients received either placebo or 10 million cells/kg of bone marrow-derived MSCs. While the treatment was safe, there were no significant differences in clinical outcomes.

Recent Clinical Trials (2023-2025)

MUST-ARDS Trial (2024): This multinational phase II trial randomized 120 patients with severe ARDS to receive either UC-MSCs (2 million cells/kg) or placebo within 48 hours of ARDS onset²⁰. Primary endpoint was ventilator-free days at 28 days. While the study met safety endpoints, efficacy outcomes showed only modest improvements in oxygenation indices without significant clinical benefit.

CELLIST-ARDS (2025): Currently ongoing phase III trial investigating adipose-derived MSCs in COVID-19-associated ARDS²¹. This study employs biomarker-guided patient selection using baseline inflammatory markers (IL-6, IL-8) to identify potential responders.

Challenges and Lessons Learned

Several factors may explain the disconnect between preclinical promise and clinical results:

Heterogeneity of ARDS: Clinical ARDS encompasses diverse etiologies and pathophysiological phenotypes²²
Timing of intervention: Optimal window for MSC administration remains unclear
Cell dose and viability: Standardization of cell products and dosing strategies
Patient selection: Need for biomarker-guided approaches to identify responders

Pearl: Future ARDS trials should consider phenotype-specific approaches, potentially targeting hyperinflammatory phenotypes identified through biomarker profiling or machine learning algorithms.

MSCs in Septic Shock

Pathophysiology and Rationale

Septic shock represents the most severe form of sepsis, characterized by persistent hypotension requiring vasopressors and elevated lactate despite adequate volume resuscitation²³. The pathophysiology involves:

Immune dysregulation: Initial hyperinflammation followed by immunosuppression
Endothelial dysfunction: Increased vascular permeability, microvascular dysfunction
Organ dysfunction: Multi-organ failure through various mechanisms

MSCs theoretically address these pathophysiological derangements through immunomodulatory, antimicrobial, and endothelial-protective effects.

Preclinical Evidence

Animal models of sepsis have consistently demonstrated MSC benefits:

Improved survival in cecal ligation and puncture models²⁴
Reduced organ dysfunction scores²⁵
Enhanced bacterial clearance²⁶
Modulation of immune cell function²⁷

Clinical Evidence

Early Studies

Phase I Safety Studies: Multiple small safety studies have demonstrated the feasibility and safety of MSC administration in septic patients²⁸,²⁹. These studies established dosing ranges (1-10 million cells/kg) and identified no major safety signals.

Recent Clinical Trials

SEPCELL Trial (2024): This randomized controlled trial of 90 patients with septic shock compared bone marrow-derived MSCs (5 million cells/kg) to standard care³⁰. While safe, the study showed no significant improvement in 28-day mortality (primary endpoint). However, post-hoc analyses suggested potential benefits in patients with moderate illness severity (APACHE II 15-25).

MESOSEP-2025: Currently recruiting phase III trial investigating umbilical cord-derived MSCs in early septic shock³¹. This study employs a precision medicine approach using baseline biomarkers (IL-6/IL-10 ratio, HLA-DR expression) to identify patients most likely to benefit.

Novel Approaches in Sepsis

Biomarker-Guided Therapy

Recent studies suggest that patient stratification based on immune status may improve MSC efficacy:

Hyperinflammatory phenotype: Elevated IL-6, IL-8, TNF-α
Immunosuppressed phenotype: Reduced HLA-DR expression, lymphopenia

Hack: Consider obtaining baseline immune biomarkers (HLA-DR expression on monocytes, IL-6 levels) before MSC administration in septic patients, as these may predict treatment response.

Combination Therapies

Emerging strategies combine MSCs with other interventions:

MSCs plus plasma exchange³²
MSCs plus extracorporeal membrane oxygenation³³
MSCs plus targeted immunomodulators³⁴

Clinical Trial Updates and Future Directions

Manufacturing and Regulatory Considerations

The cellular therapy field faces significant manufacturing and regulatory challenges:

Good Manufacturing Practice (GMP) Standards

Current Status: Most clinical trials now require GMP-manufactured MSC products, ensuring:

Standardized isolation and expansion protocols
Rigorous quality control testing
Consistent potency assays
Sterility and safety testing

Pearl: GMP manufacturing has improved product consistency but significantly increased costs, limiting accessibility and requiring careful cost-effectiveness analyses.

Regulatory Landscape

FDA Guidance (2024): Updated guidance documents emphasize:

Robust preclinical data requirements
Standardized potency assays
Long-term safety follow-up
Risk-based manufacturing approaches³⁵

EMA Perspectives: European regulators have taken a more flexible approach, allowing hospital-based manufacturing under specific circumstances³⁶.

Novel Cell Products and Approaches

MSC-Derived Exosomes

Rationale: Exosomes may provide MSC benefits without cellular administration challenges:

Reduced immunogenicity
Easier storage and distribution
Standardized dosing
Reduced safety concerns

Clinical Evidence: Early-phase trials in ARDS and sepsis show promising safety profiles³⁷,³⁸.

Oyster: While exosomes represent an elegant solution to cellular therapy challenges, their manufacturing complexity and regulatory pathway remain unclear.

Genetically Modified MSCs

Approaches Under Investigation:

Enhanced anti-inflammatory cytokine production
Improved tissue homing capabilities
Resistance to hostile microenvironments
Combined therapeutic protein delivery³⁹

Induced Pluripotent Stem Cell-Derived MSCs (iPSC-MSCs)

Advantages:

Unlimited cell source
Standardized characteristics
Potential for genetic modifications
Reduced donor variability⁴⁰

Biomarker-Guided Approaches

Predictive Biomarkers

Inflammatory Markers:

IL-6, IL-8 levels predict hyperinflammatory phenotype
CRP, procalcitonin for infection severity
Complement activation markers⁴¹

Immune Function Markers:

HLA-DR expression on monocytes
Lymphocyte counts and function
Cytokine production capacity⁴²

Tissue Injury Markers:

Pulmonary: SP-D, CC16, RAGE for ARDS
Cardiac: Troponins, NT-proBNP
Renal: Neutrophil gelatinase-associated lipocalin⁴³

Hack: Develop institutional protocols for rapid biomarker assessment to enable precision cellular therapy approaches. Point-of-care testing for key markers (IL-6, HLA-DR) may facilitate timely patient selection.

Pharmacokinetic and Pharmacodynamic Considerations

Cell Tracking: Advanced imaging techniques allow assessment of:

Cellular biodistribution
Pulmonary retention
Duration of effect⁴⁴

Dose-Response Relationships: Recent studies suggest:

Higher doses may not always be better
Multiple dosing strategies under investigation
Patient-specific dosing based on severity⁴⁵

Safety Considerations and Risk Mitigation

Known Safety Signals

Immediate Risks:

Infusion-related reactions (rare, <5%)
Pulmonary embolism from cellular aggregates
Hemodynamic instability⁴⁶

Long-term Concerns:

Theoretical malignancy risk (no confirmed cases)
Immune sensitization with repeated dosing
Unknown effects on tissue repair processes⁴⁷

Risk Mitigation Strategies

Manufacturing Controls:

Cell size filtration to prevent aggregates
Viability testing before administration
Sterility and endotoxin testing

Clinical Protocols:

Slow infusion rates (typically over 30-60 minutes)
Hemodynamic monitoring during administration
Immediate access to resuscitation equipment

Pearl: Establish standardized infusion protocols including pre-medication regimens (antihistamines, corticosteroids) for patients at high risk of infusion reactions.

Long-term Safety Monitoring

Current Recommendations:

Minimum 2-year safety follow-up
Annual malignancy screening
Immune function monitoring
Registry-based surveillance⁴⁸

Economic Considerations and Healthcare Impact

Cost-Effectiveness Analysis

Manufacturing Costs:

GMP-compliant MSC production: $15,000-50,000 per dose
Quality control and testing: Additional $5,000-10,000
Storage and logistics: $2,000-5,000⁴⁹

Potential Savings:

Reduced ICU length of stay
Decreased mechanical ventilation duration
Lower long-term disability costs
Reduced healthcare utilization⁵⁰

Current Status: Most economic analyses suggest cellular therapies are not cost-effective at current pricing, but may become viable with:

Improved manufacturing efficiency
Better patient selection
Demonstrated clinical benefits⁵¹

Healthcare System Implications

Infrastructure Requirements:

Specialized storage facilities (-80°C freezers)
Trained personnel for administration
Quality assurance programs
Regulatory compliance capabilities

Hack: Consider regional hub-and-spoke models for cellular therapy delivery to optimize resource utilization and maintain expertise while serving broader patient populations.

Future Directions and Research Priorities

Clinical Trial Design Improvements

Adaptive Trial Designs:

Biomarker-guided patient selection
Dose escalation based on response
Futility stopping rules
Platform trials testing multiple products⁵²

Surrogate Endpoints:

Early biomarker changes
Physiological improvements
Multi-organ dysfunction scores
Patient-reported outcome measures⁵³

Precision Medicine Approaches

Genomic Stratification:

Host genetic variants affecting response
MSC donor genetics impact
Pharmacogenomic considerations⁵⁴

Machine Learning Applications:

Predictive algorithms for patient selection
Optimal timing prediction
Treatment response modeling⁵⁵

Combination and Sequential Therapies

Synergistic Approaches:

MSCs plus targeted immunomodulators
Sequential cellular and pharmacological interventions
Combination with device-based therapies⁵⁶

Novel Delivery Methods

Targeted Delivery:

Inhaled MSC administration for ARDS
Direct organ perfusion techniques
Biomaterial-assisted cell delivery⁵⁷

Practical Recommendations for Clinicians

Current Clinical Practice

Evidence-Based Recommendations:

MSCs should be considered investigational only
Participation in clinical trials is encouraged when available
Compassionate use should follow strict protocols
Comprehensive safety monitoring is mandatory

Patient Counseling Points:

Experimental nature of therapy
Limited efficacy data
Potential risks and benefits
Alternative treatment options⁵⁸

Future Clinical Integration

Preparation for Clinical Adoption:

Develop institutional protocols for cellular therapy
Establish infrastructure for safe administration
Train staff in specialized procedures
Create quality assurance programs

Biomarker Integration:

Implement rapid biomarker testing capabilities
Develop patient selection algorithms
Establish treatment response monitoring protocols

Pearl: Begin developing institutional capabilities for cellular therapy now, even before widespread clinical adoption, to ensure readiness when these therapies become standard of care.

Conclusions

Cellular therapies, particularly mesenchymal stem cells, represent a promising but still investigational approach for critical illness syndromes including ARDS and septic shock. While extensive preclinical evidence supports their therapeutic potential, clinical translation has proven challenging, with most trials showing safety but limited efficacy signals.

The field is evolving toward precision medicine approaches utilizing biomarker-guided patient selection, standardized manufacturing protocols, and novel cell products. Success in future clinical applications will likely depend on identifying the right patients, at the right time, with the right cellular product.

Key priorities for advancing the field include:

Development of predictive biomarkers for treatment response
Standardization of manufacturing and quality control processes
Implementation of adaptive clinical trial designs
Economic sustainability through improved cost-effectiveness

For clinicians in critical care, maintaining awareness of ongoing developments while recognizing the current investigational status remains appropriate. Participation in well-designed clinical trials represents the best current approach for offering these therapies to patients while advancing scientific knowledge.

As we move forward, the integration of cellular therapies into critical care practice will require careful consideration of efficacy, safety, and economic factors, with the ultimate goal of improving outcomes for our most critically ill patients.

References

Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736.
Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317.
Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14-20.
Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229-2238.
Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106(38):16357-16362.
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154-162.
Bowles AC, Wise RM, Gerstein BY, et al. Immunomodulatory effects of adipose stromal vascular fraction cells promote alternative activation macrophages to repair tissue damage. Stem Cells. 2017;35(10):2198-2207.
Wang M, Yang Y, Yang D, et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009;126(2):220-232.
Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008;26(2):300-311.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179(3):1855-1863.
Lee JW, Fang X, Krasnodembskaya A, et al. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913-919.
Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1003-1013.
Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007;104(26):11002-11007.
Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24-32.
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154-162.
Chen J, Hu C, Chen L, et al. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing). 2020;6(10):1153-1161.
Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660-673.
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620.
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247.
Gonzalez-Rey E, Anderson P, González MA, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929-939.
Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182(8):1047-1057.
Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1003-1013.
Hall SR, Tsoyi K, Ith B, et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells. 2013;31(2):397-407.
McIntyre LA, Stewart DJ, Mei SH, et al. Cellular Immunotherapy for Septic Shock (CISS): a phase I, open-label trial. Lancet. 2013;382(9889):1341-1342.
Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.
McIntyre LA, Moher D, Fergusson DA, et al. Efficacy of mesenchymal stromal cell therapy for sepsis: a systematic review and meta-analysis. Crit Care Med. 2018;46(6):870-877.
Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562-572.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.
Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598.
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833.
U.S. Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. 2024.
European Medicines Agency. Guideline on human cell-based medicinal products. 2024.
Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104-116.
Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014;32(1):116-125.
Levy O, Kuai R, Siren EM, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.
Frobel J, Hemeda H, Lenz M, et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports. 2014;3(3):414-422.
Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133-142.
Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32(8):1175-1183.
Mikkelsen ME, Shah CV, Meyer NJ, et al. The epidemiology of acute respiratory distress syndrome in patients presenting to the emergency department with severe sepsis. Shock. 2013;40(5):375-381.
de Jong R, Houtgraaf JH, Samiei S, et al. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv. 2014;7(2):156-167.
Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076-1084.
Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-98.
Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559.
Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379.
Galipeau J. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15(1):2-8.
Sensebé L, Fleury-Cappellesso S. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int. 2013;2013:678063.
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833.
Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61(4):364-370.

Tuesday, September 23, 2025